ozanimod

Celgene's timeline for refiling ozanimod gets mixed reviews
Celgene's timeline for refiling ozanimod gets mixed reviews
Biopharma Dive
Celgene
ozanimod
MS
multiple sclerosis
FDA
Flag link:
A metabolite will make or break Celgene's ozanimod
A metabolite will make or break Celgene's ozanimod
Biopharma Dive
Celgene
ozanimod
MS
multiple sclerosis
metabolite
Flag link:
Celgene's Ozanimod Reduces Relapses and Brain Volume Loss in MS Patients in Phase III Trials
Celgene's Ozanimod Reduces Relapses and Brain Volume Loss in MS Patients in Phase III Trials
CP Wire
Celgene
ozanimod
relapsing multiple sclerosis
MS
Flag link:
Celgene's Ozanimod Reduces Relapses and Brain Volume Loss in MS Patients in Phase III Trials
Celgene Corporation
multiple sclerosis
ozanimod
Flag link:
Arena Pharmaceuticals Takes Aim at Celgene
Arena Pharmaceuticals Takes Aim at Celgene
Motley Fool
Arena Pharmaceuticals
Celgene
etrasimod
ozanimod
ulcerative colitis
Flag link:
How Bad Is Celgene's FDA Foul-Up? Two Decades Of Biotech History Says It Can't Be Good
How Bad Is Celgene's FDA Foul-Up? Two Decades Of Biotech History Says It Can't Be Good
Forbes
Celgene
biotech
FDA
RTF letters
ozanimod
Flag link:
Celgene stumbles again, as FDA declines to review multiple sclerosis drug critical to company future
Celgene stumbles again, as FDA declines to review multiple sclerosis drug critical to company future
Stat
Celgene
FDA
MS
multiple sclerosis
ozanimod
Flag link:
Celgene's Future Growth Could Depend on a Competitor's Trial This Quarter
Celgene's Future Growth Could Depend on a Competitor's Trial This Quarter
Motley Fool
Celgene
etrasimod
ozanimod
Arena Pharmaceuticals
MS
multiple sclerois
Flag link:
3 Big Biotech Stocks With Major Catalysts on the Way
3 Big Biotech Stocks With Major Catalysts on the Way
Motley Fool
biotech
AbbVie
Neurocrine Biosciences
Elagolix
Celgene
ozanimod
Gilead Sciences
bictegravir
Flag link:
5 Biggest New Drugs of 2018
5 Biggest New Drugs of 2018
Motley Fool
Gilead Sciences
Bictegravir/F/TAF
Novo Nordisk
semaglutide
Ozempic
Incyte
epacadostat
AbbVie
Rova-T
Celgene
ozanimod
Flag link:
The top 10 prospective blockbuster drug launches slated for 2018 — Evaluate
The top 10 prospective blockbuster drug launches slated for 2018 — Evaluate
Endpoints
drug launches
Bictegravir/F/TAF
Gilead Sciences
semaglutide
Novo Nordisk
epacadostat
Incyte
Rova-T
AbbVie
ozanimod
Celgene
apalutamide
JNJ
Elagolix
AVXS-101
AveXis
lanadelumab
Shire
Epidiolex
GW Pharma
Flag link:
Late-stage ozanimod data brings Celgene closer to filing
Late-stage ozanimod data brings Celgene closer to filing
BioPharma Dive
ozanimod
Celgene
MS
multiple sclerosis
Flag link:
How Big of a Deal Is Celgene's Flop?
How Big of a Deal Is Celgene's Flop?
Motley Fool
Celgene
GED-301
Crohn’s disease
ozanimod
Otezla
Flag link:
5 Drugs That Could Make Celgene the Best Biotech Stock of the Next Decade
5 Drugs That Could Make Celgene the Best Biotech Stock of the Next Decade
Motley Fool
Celgene
ozanimod
GED-0301
luspatercept
marizomib
CC-220
Flag link:
Ozanimod Could Drive Celgene’s Long-Term Growth
Ozanimod Could Drive Celgene’s Long-Term Growth
Market Realist
ozanimod
Celgene
Flag link:
These 5 Drugs Could Be Worth $45 Billion -- and They're Not Even on the Market Yet
These 5 Drugs Could Be Worth $45 Billion -- and They're Not Even on the Market Yet
Motley Fool
Biogen
aducanumab
JNJ
apalutamide
Eli Lilly
abemaciclib
AbbVie
Rova-T
Celgene
ozanimod
Flag link:
Biotechs Find Strength In Numbers In Treating Multiple Sclerosis
Biotechs Find Strength In Numbers In Treating Multiple Sclerosis
Investors Business Daily
MS
multiple sclerosis
Roche
Celgene
Novartis
Biogen
ozanimod
Gilenya
Ocrevus
Extavia
Flag link:
Celgene touts ozanimod MS data, but disability benefit weak over rival med
Celgene touts ozanimod MS data, but disability benefit weak over rival med
Fierce Biotech
Celgene
ozanimod
MS
multiple sclerosis
Biogen
Avonex
Flag link:
Celgene highlights MS drug in diversification push
Celgene highlights MS drug in diversification push
BioPharma Dive
Celgene
MS
multiple sclerosis
ozanimod
Flag link:
3 Big Biotech Stocks With Big-Time Catalysts
3 Big Biotech Stocks With Big-Time Catalysts
Motley Fool
Regeneron
Praluent
Amgen
biosimilars
Amjevita
Humira
ABP-215
Avastin
ABP-980
Herceptin
Celgene
ozanimod
Flag link:

Pages